Idera Pharmaceuticals Inc (IDRA)

[jaybe]

New 3GA patent app published yesterday...

This one specifically covers compounds that inhibit single point mutations BRAF 600VE (melanoma) and MyD88 L265P (Waldenstr6m's macroglobulinemia) while sparing wild type.

3GA patent app for compounds modulating essentially all immune checkpoints (PDl, PDLl, IDOl, LAG3, TIM3, CTLA4, ID02, CEACAMl, OX40) was published in February.

I suspect patent app supporting IDRA-008 in a liver target will be published in the next month or so, hence the timing of the disclosure.


https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017205384&recNum=1&office=&queryString=FP%3A%28idera+pharmaceuticals%29&prevFilter=&sortOption=Pub+Date+Desc&maxRec=369